The more selective BTK inhibitor zanubrutinib offers better tolerability and possibly better efficacy than ibrutinib for patients with Waldenström macroglobulinemia, an Australian study has shown. Presented at the ASCO 2020 virtual meeting by Professor Con Tam of the Peter MacCallum Cancer Centre in Melbourne, the results of the ASPEN Phase III study showed zanubrutinib was ...
BTK inhibitors go head-to-head in Waldenström macroglobulinemia
By Michael Woodhead
11 Jun 2020